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INTRODUCTION

Aldosterone,

the most potent of the mineralocorticolds

secreted by the adrenal cortex, plays a prominent role in the
regulation of water and electrolyte metabolism in normal and in
certain pathological states.

Since many features of its biological

activity are as yet incompletely understood,

the utilization of

a compound capable of reversing or antagonizing its effect would
provide a convenient investigative tool.

In 1957 Kagawa et al.

( 1 ) reported that a synthetic steroidal spirolactone SC-5233 or
its

19-nor analogue SC-8109 reversibly blocked the renal tubular

effects of desoxycorticosterone acetate in adrenalectomized rats
whereas neither of the spirolactones affected urinary electrolytes
by itself.

Recently Liddle ( 2 ) reported that SC-8109 reverses the

renal tubular effects of aldosterone or biologically similar
steroids such as DOCA in human subjects.

In addition he reported

that when patients with Addison’s disease were maintained on a
high sodium diet without steroid therapy,

the administration of

spirolactone had little or no effect on urinary electrolytes.
These same patients maintained on a high sodium diet plus DOCA
responded to spirolactone in a manner simulating the abrupt with¬
drawal of the renal effects of aldosterone.

On the basis of these

findings it has been suggested that spirolactone blocks the renal
tubular effects of aldosterone.
The present investigation was designed to determine whether
spirolactone’s effect of reducing aldosterone activity is
to the kidney.
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MATERIALS AND METHODS

Sub jects
Three patients with Laennec Ts cirrhosis and intractible
ascites were

studied.

In each case the diagnosis was histologically

established by liver biopsy performed prior to the investigation.
One patient was studied on two occasions separated by a period of
8 months.

To distinguish between these,

they will be designated

AC-I and AC-II and will be considered separately in the text.
Pertinent clinical findings are recorded in Table 1.
case the history revealed heavy alcholic intake
habits.

In each

and poor dietary

In all three patients previous treatment with bed rest,

low sodium diet (10 mEq. per day), mercurial diuretics,

and

chlorthiazide had been ineffective in bringing about sodium and
water loss.

In addition RO had received a prior course of intra¬

venous albumin with no resultant change in weight.

None had

other significant illness or evidence of gastro-intestinal bleeding.

Program of study
Each subject was placed on a diet which included a daily intake
of 10 mEq.
protein.

of sodium,

23>00 calories,

and from 60 to 80 grams of

Potassium intake was not regulated, but no potassium

other than that contained in the diet was given.

There was no

restriction of fluid Intake.
Daily Z\\ hour urine specimens were collected under mineral
oil with thymol crystals added as a preservative.
were weighed at the same

time each day.

Urine volume was recorded

and the samples analyzed for sodium, potassium,
titratable acidity.

The subjects

pH,

ammonium,

and

.

3
Saliva specimens were obtained at the same time each day in
the following manner: after washing his mouth out with water,
subject chewed a piece of paraffin,

the

expectorating all saliva into

a sodium and potassium free container until 7 cc. were obtained.
Serum sodium, potassium,

chloride,

and bicarbonate concentrations

were determined twice during the control period and at suitable
intervals throughout the study.
The

subjects were observed carefully for any signs of drug

toxicity,

including changes in vital signs,

function,

and mental status.

gastro-intestinal

The skin was examined for any changes,

especially at the site of injection.
Blood samples from each subject were analyzed before and after
administration of the drug to detect any changes in hematocrit,
white blood cell count,

serum proteins,

liver function tests,

and either blood urea nitrogen or non-protein nitrogen.
After a 3-d.ay control period each subject was given a 1-day
course of SC-8109 administered in 8 divided doses given every
3 hours.

In studies in which more than 1 dosage range was used,

a subsequent dose was not administered until urinary excretion of
sodium had returned to the control level.
The dosages and routes of administration of the drug are
recorded in Table 2.

AG became hyponatremic

(serum sodium

z 120 mEq./liter) during the first study period following an
intramuscular dose of 800 mg.

and was treated with 20 gms.

of

NaCl by mouth and restriction of fluid intake over a period of
6 days at the end of the study (Fig.

1).

k
Me thod s
Urinary,

salivary,

and serum sodium and potassium were determined

on a Patwin flame photometer.

Urinary ammonium was analyzed by the

micro-diffusion method of Conway; titratable acidity by the method of
Henderson and Palmer (3)?
meter.

and pH on a Cambridge electron ray pH

Serum chloride was determined by the method of Schales and

Schales (4) and bicarbonate by the method of Van Slyke and Neill (5)*

RESULTS
The results of the

studies are illustrated in Figs.

1-4*

Effects on urinary sodium and potassium
On the day of administration of SC-8109 urinary sodium excretion
generally rose above the control levels of 1 to 5 mEq. per day and
then fell slowly to control levels.
were noted:

in AC-II

which time the

(Fig.

2)

Two exceptions to this pattern

the rise continued for four days, at

study was discontinued; and in DS

dose had no demonstrable effect.

(Fig.

3)

The greatest 24 hour sodium excre¬

tion attained by the three subjects receiving the 800 mg.
dose was between 37 and 49 mEq.

the 100 mg.

(Figs. 1,

3>

intramuscular

and 4)«

In no subject was urinary potassium significantly increased by
the administration of SC-8109,

and in AC-II there was a sizable

decrease following drug administration.
roughly paralleled sodium excretion,

The rise in Na/K ratio

and in both studies of AC a

concomitant decrease in potassium excretion augmented the effect of
the increased sodium loss on the ratio.
Na/K ratios rose to a level between 4 and 6 times control values
after administration of the 800 mg. dose.

The highest ratio reached,

1.3, was in the first study of AC following the administration of

400 mg. intramuscular dose.
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Effect on urinary hydrogen ion
AC-I and RO excreted decreased amounts of titratable acid
for 3 and

4 days respectively following the administration of SC-8109*

There was a concomitant small decrease in ammonium excretion in
RO and a rather large decrease for 1 day in AC.

Urinary pH rose

in RO from a control level of about 6.0 to a level of 6.8 three
days after the administration of the drug,

and in AC-I from

6.4

to 7.0 four days after administration.
The drug had no significant effect on urinary pH,
acidity,

or ammonium in DS.

titratable

The increased urinary ammonium and

pH and decreased titratable acidity noted on day 6,

three days

after DS received a 100 mg. parenteral dose of SC-8109, coincided
o
with an elevation of temperature to 101
P.
The hydrogen ion
changes were attributed to a transient urinary tract infection,
but this was not definitely established.

Effect on urine volume
In general, parenterally administered SC-8109 had a much less
dramatic effect on urine volume than comparable doses given orally.
Parenteral administration of 800 mg. SC-8109 raised the urinary
volume by an average of 175 cc. for a period of
was in striking contrast to the effects of an

4 or 5 days.

This

800 mg. oral dose,

which increased the urine volume by more than a liter a day for a
period of two days (see '’Comparison of dose and route”).

Effect on the saliva
Salivary sodium and potassium studies were carried out on all
3 subjects.

A significant change occurred in one,

suggestive change in another.

and there was a
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Salivary Na/K ratios rose on the day of administration of all
doses to DS,

the most significant rise occurring after the 800 mg.

oral dose when the ratio rose from 0.35 to 0.55*

The changes in

ratio were usually due to both increased sodium and decreased
potassium concentrations,

but the 0.55 value was due to a significant

decrease in potassium.
In the first study of AC, the salivary Na/K ratio rose to its
highest level,

O.36,

intramuscular dose.

the day after administration of [j_00 mg.
There was no significant change after the

800 mg. dose, but at that time her serum sodium was depressed, and
this may have affected the

salivary sodium concentration.

Effect on Weight
In subjects AC-I and R0 there was a significant loss of
weight within one or two days following the administration of
SC-8IO9.

RO lost 0.7 kilos following a 800 mg. parenteral dose

and AC-I lost 0.8 kilos following a 400 mg. dose by the same route.
Oral administration of 800 mg.

to DS was followed by a leveling-off

and slight reversal of a previously relentless weight increase.
Weight changes may have been obscured in some of the studies by
the uncontrolled fluid intake.
Comparison of dose and route
Response to SC-8109 appeared to be affected by the size of
the dose and the route of administration.
In general It was found that the greater the dose administered
the greater the response.
DS,

This was exemplified by the response of

in terms of sodium excretion,

to 100, ipOO,

and 800 mg. parenteral

•'

' •

*

.
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doses; no increase with the first,
crease with the second,
third (Pig.

very small but significant in¬

and a relatively large increase with the

3)«

Similarly AC-I had a greater response

to I|.00 mg.

than to

100 mg.jhowever there was no further increase in response to 800 mg.
This was most likely due to the decrease in serum sodium,

the

resultant decrease in filtered load of sodium causing a decrease
in the amount delivered to the tubules.

The subject may also have

been secreting a greater quantity of aldosterone as a response to
the lowering of the serum sodium.
Oral and parenteral dose responses can be compared in DS.
The oral dose resulted in a more abrupt rise and fall in urinary
sodium excretion with a higher peak.

Maximal effect was noted on

the first day with the oral dose and on the second day with the
intramuscular dose.

The peak effect of an 800 mg. dose administered

orally was a sodium excretion of 44 mEq. per day;

that of 800 mg.

given parenterally an excretion of 30 mEq. per day.

Whereas it

took only 3 days following the oral dose for urinary sodium excretion
to return to control levels,
dose.

it took 6 days following the parenteral

The total quantity of sodium lost after treatment by the

two routes was approximately equal.
electrolytes occurred after 800 mg.

More marked effects on salivary
given orally than after a

comparable intramuscular dose.

Side effects
There was no change in vital signs or mental status in any of
the subjects, and there was no significant change in blood urea
nitrogen,
tests

non-protein nitrogen,

serum proteins,

or liver function

*

I

-

to

l

j

8
No reaction or discomfort at the site of injection was
encountered.
DS had a nose bleed on the day he received the I4.OO mg.
intramuscular dose.

3

200,000 per mm ,

Platelet counts done that day were over

and prothrombin time was 26% of normal.

prothrombin level during the control period was $5%.
of Vit. K-^ were given,
AC,

The

Fifty mg.

and the prothrombin level rose above l±5%»

in whom long-standing esophageal varices had been

demonstrated by X-ray, had experienced intermittent gastro¬
intestinal disturbances for over a year prior to this investigation.
The second study of this

subject was discontinued I4. days after

administration of SC-8109 because of an exacerbation of those
complaints,
varices.

and the following day the patient bled from esophageal

In view of the antecedent complaints and the previous

demonstration of varices, it is unlikely that these symptoms were
due to the drug.
The hyponatremia encountered in AC was a disturbing complica¬
tion of treatment.
first period (Fig.

Serum sodium fell in both studies; during the
1)

this was associated with a decrease in all

other serum electrolytes; during the second period (Fig.
the other electrolytes were unaffected.

2)

In the first instance

the hyponatremia was probably the result of urinary salt depletion
complicated by serum dilution related to uncontrolled water intake.
Strict fluid restriction and an oral intake of 20 gms. of NaCl over
a period of 6 days following the first study brought the serum
sodium from a level of 120 mEq./liter back to the control level of
131 mEq./liter.
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DISCUSSION

Patients with cirrhosis who are accumulating ascites have
been found to excrete in their urine only a small fraction of
the sodium they ingest.

This avid sodium retention, manifested

not only in the urine but also in saliva,

sweat,

and feces,

is

associated regularly with greatly elevated urinary levels of the
sodium-retaining hormone,
reflect, presumably,

aldosterone (7).

Both of these findings

increased secretion and activity of the

hormone.
Postulating that decreased activity of aldosterone might
halt the fluid retention,

Marson ( 8 )

and Guiseffi et al.

( 9 )

performed total adrenalectomies on patients with cirrhosis and
intractible ascites,

achieving significant but incomplete diuresis

and sodium loss.
Amphenone, which inhibits the biogenesis of several adreno¬
cortical hormones including aldosterone, has been used to the same
end (10).

Its usefulness, however, is limited by its toxicity.

The synthetic steroidal spirolactone SC-8109 is reported to
be active only in the presence of elevated levels of endogenous
or exogenous aldosterone or biologically similar steriods,
their renal tubular actions competitively.

blocking

In this study the

effects of this compound on electrolyte and water metabolism in
different end organ sites of aldosterone activity were investigated.
With both oral and parenteral administration of SC-8109 there
was a marked increase in the urinary Na/K ratio.

It Is evident that

because of the small amounts of urinary sodium excreted during the
control periods,

an approximately equal increase in both sodium

and potassium excretion would result in a significant increase in
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10
the Na/K ratio.

This has been observed following the administration

of diuretics such as mercurials or carbonic anhydrase inhibitors
More significant here is the

( 2 ).

fact that increased Na/K ratios occurred

in the absence of any increase in potassium excretion;

there is a

suggestion that potassium excretion was actually decreased following
the administration of the compound in two of the subjects.
Two studies indicated that even at the time of maximal
sodium and water diuresis, hydrogen ion excretion,
urinary pH,

ammonium,

as measured by

and titratable acidity, was decreased.

There

was no observed effect on urinary hydrogen ion in one of the subjects.
Thus,

there was increased sodium excretion and either decreased

or unchanged potassium excretion on all three subjects and decreased
hydrogen ion excretion in two of these.
aldosterone is

Since the renal effect of

to decrease sodium excretion and to increase

potassium and hydrogen ion excretion (1 ),

the urinary electrolyte

findings reported here are consistent with the view that SC-8109
inhibits the activity of aldosterone in the kidney.
Aldosterone decreases sodium and/or increases potassium
concentration in saliva,
urine (11).

sweat,

and feces as well as in the

To test the hypothesis

that the administration of

SC-8109 results in decreased aldosterone activity throughout the
body,

studies of salivary sodium and potassium were carried out.

Certain diuretics such as the mercurials raise the urinary Na/K
ratio but have no effect on the salivary electrolytes.

In contrast,

SC-8IO9 caused a change in the salivary Na/K ratio in 2 of the 3
subjects studied which was consistent with a decrease in aldosterone
activity.
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11.
Decreased aldosterone activity could be brought about in a
number of ways,

including decreased secretion,

losses and/or increased inactivation,
inhibition.

increased urinary

as well as by competitive

The exact mechanism of action of SC-8109 cannot be

determined from the data available at present.

Certain inferences

can be made, however.
The fact that the compound is active in adrenalectomized
animals given desoxycorticosterone acetate or aldosterone indicates
that its mechanism is not primarily supression of secretion.
Indeed, Bolte et al.

(12) found that in 2 patients with cirrhosis

urinary excretion of

aldosterone rose eight times above the control

level following, the administration of SC-8109,
ably due to increased secretion.

a finding presum¬

It is unlikely that spirolactone

acts by increasing losses of aldosterone in the urine,
Leutcher’s findings that

in view of

the compound blocked the action of

aldosterone in a patient with nephrosis without changing urinary
aldosterone.

The relationship between aldosterone secretion and

urinary excretion is somewhat obscured by the fact that urinary
aldosterone as now measured by chromatographic methods represents
only 5 to 10% of the daily secretion (13).
The most probable action of spirolactone remains that of
competitive inhibition at the end organ site of aldosterone activity.
However the remote possibility that it acts by increasing inactiva¬
tion of the hormone cannot be excluded.
The finding of this study suggest that SC-8109 may be of thera¬
peutic value in patients with cirrhosis and ascites.
has the advantage of inducing a

The compound

sodium and water diuresis without

any accompanying increase in potassium excretion.

As with other
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12
diuretics, hyponatremia must be considered a possible hazard.

Whether

spirolactone is effective and free of toxic effects when given over
a long period remains to be seen.

SUMMARY AND CONCLUSIONS

Pour studies were carried out on cirrhotics with intractible ascites, presumably associated with increased aldosterone
activity,

to determine whether the synthetic steroidal

spirolactone SC-8109 reduces this activity in the kidney and
salivary glands.
The effects of the compound on urinary electrolytes were
consistent with a decreased aldosterone effect in the kidney in
all the subjects studied.
Its effects on salivary electrolytes were consistent with a
decreased aldosterone effect in one subject and suggestive of
this in another.
The reduction of aldosterone activity brought about by
SC-8109 thus is not limited to the renal tubule.
The most probable mechanism of action of SC-8IO9 is
competitive inhibition of aldosterone activity at its site of
action in the tissues.
The possible
determined.

therapeutic value of SC-8109 remains to be
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TABLE

1•

INITIAL CLINICAL AND LABORATORY FINDINGS

Patient

DS

AC-I

56 yr. M

69 yr. F

70 yr. F

67 yr. M

Severity

4/

2/

3/

3/

Duration

3 yr.

6 mo.

1 yr.

3 mo.

Pedal edema

none

none

1/

none

Serum Na (mEq/Liter)

139

133

llil

141

Serum K

(mEq/liter)

4-5

4.7

44

4.5

Total protein (gm.%)

6.1

6.9

5*5

6.7

Alb./Glob.

2.7/34

2.1/4.8

1.6/3.9

2.9/3.8

Total bilirubin (mg.%)

1.32

1.26

1.28

1.38

Bromsulphalein retention (%)

3,0 o2%

iW

--

32%

--

--

25

Age and sex

AC-II

RO

Ascites

(gm.$)

Blood urea N.
Non-protein N.

(mg.
(mg.

%)
%)

23
—

34

33

--
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TABLE

2.

DOSE A ED ROUTE OF ADMINISTRATION OF SC-8109

Intramuscular

AC-I

(Fig. 1)

AC - II

(Pig. 2)

DS

(Pig. 3)

RO

(Fig. 4)

Oral

100 mg.

400 mg.

800 mg.

X

X

X

1|00 mg.

800 1

X
X

X

X
X

X

X

ll I

.

'

i

)

.

1 •-

15.

FIG. I.
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